In this direction, zenocutuzumab, a HER2-HER3 bispecific antibody combined with ET, has demonstrated encouraging antitumor effects in xenograft models, opening the window to a new possible chemotherapy-free approach for patients with endocrine-resistant HER2-low BC [50]. The gene discussed is ERBB2; the disease is breast cancer.